Trial · NCT01313663
Results by group76
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 76
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Pemetrexed 500 mg/m^2 | 10.3 | 90% Confidence Interval 5.3 to NA | weeks | |
| Progression Free Survival (PFS) | Pazopanib 800 mg | 12.7 | 90% Confidence Interval 6.0 to NA | weeks | |
| Number of Participants (Par.) With the Indicated Best Overall Response | Pemetrexed 500 mg/m^2 | CR | 0 | participants | |
| Number of Participants (Par.) With the Indicated Best Overall Response | Pazopanib 800 mg | CR | 0 | participants | |
| Number of Participants (Par.) With the Indicated Best Overall Response | Pemetrexed 500 mg/m^2 | PR | 0 | participants | |
| Number of Participants (Par.) With the Indicated Best Overall Response | Pazopanib 800 mg | PR | 0 | participants | |
| Number of Participants (Par.) With the Indicated Best Overall Response | Pemetrexed 500 mg/m^2 | SD | 2 | participants | |
| Number of Participants (Par.) With the Indicated Best Overall Response | Pazopanib 800 mg | SD | 2 | participants | |
| Number of Participants (Par.) With the Indicated Best Overall Response | Pemetrexed 500 mg/m^2 | PD | 4 | participants | |
| Number of Participants (Par.) With the Indicated Best Overall Response | Pazopanib 800 mg | PD | 4 | participants | |
| Number of Participants (Par.) With the Indicated Best Overall Response | Pemetrexed 500 mg/m^2 | Not evaluable | 3 | participants | |
| Number of Participants (Par.) With the Indicated Best Overall Response | Pazopanib 800 mg | Not evaluable | 5 | participants | |
| Number of Participants With Any Non-serious On-therapy Adverse Event (AE: Occurring in >=5% Participants in Any Treatment Arm) and Serious Adverse Event (SAE) | Pemetrexed 500 mg/m^2 | Non-serious AEs | 9 | participants | |
| Number of Participants With Any Non-serious On-therapy Adverse Event (AE: Occurring in >=5% Participants in Any Treatment Arm) and Serious Adverse Event (SAE) | Pazopanib 800 mg | Non-serious AEs | 9 | participants | |
| Number of Participants With Any Non-serious On-therapy Adverse Event (AE: Occurring in >=5% Participants in Any Treatment Arm) and Serious Adverse Event (SAE) | Pemetrexed 500 mg/m^2 | SAEs | 2 | participants | |
| Number of Participants With Any Non-serious On-therapy Adverse Event (AE: Occurring in >=5% Participants in Any Treatment Arm) and Serious Adverse Event (SAE) | Pazopanib 800 mg | SAEs | 2 | participants | |
| Time on Study Treatment (Pazopanib), as a Measure of Extent of Exposure | Pazopanib 800 mg | 1.8 | Standard Deviation 1.02 | months | |
| Mean Daily Dose, as a Measure of Extent of Exposure | Pazopanib 800 mg | 751.3 | Standard Deviation 82.85 | milligrams | |
| Mean Number of Pemetrexed Dosing Cycles, as a Measure of Extent of Exposure | Pemetrexed 500 mg/m^2 | 5.2 | Standard Deviation 5.49 | number of cycles | |
| Average Dose of Pemetrexed for All Cycles, as a Measure of Extent of Exposure | Pemetrexed 500 mg/m^2 | 499.54 | Standard Deviation 30.222 | milligrams per meters squared (m^2) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01313663/results